Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBITDA: 2017-2024

Historic EBITDA for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$593.0 million.

  • BridgeBio Pharma's EBITDA rose 24.28% to -$145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$609.9 million, marking a year-over-year decrease of 12.04%. This contributed to the annual value of -$593.0 million for FY2024, which is 2.37% up from last year.
  • Latest data reveals that BridgeBio Pharma reported EBITDA of -$593.0 million as of FY2024, which was up 2.37% from -$607.4 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's EBITDA registered a high of -$474.5 million during FY2020, and its lowest value of -$607.4 million during FY2023.
  • Its 3-year average for EBITDA is -$570.8 million, with a median of -$593.0 million in 2024.
  • In the last 5 years, BridgeBio Pharma's EBITDA tumbled by 78.22% in 2020 and then climbed by 11.17% in 2022.
  • BridgeBio Pharma's EBITDA (Yearly) stood at -$474.5 million in 2020, then decreased by 21.53% to -$576.6 million in 2021, then grew by 11.17% to -$512.2 million in 2022, then decreased by 18.58% to -$607.4 million in 2023, then increased by 2.37% to -$593.0 million in 2024.